Prior to Agent Capital, Dr. New was a Principal at Baxalta Ventures, the corporate venture capital arm of Baxalta, where she led venture capital investments and served as a board observer for Gadeta BV, Syntimmune, and Vitesse Biologics. Prior to Baxalta, Dr. New was a Senior Associate at Baxter Ventures, the corporate venture capital arm of Baxter, where she supported scientific diligences, financial modeling, investment closings, and competitive market analyses, and also aided formation of academic new company spinouts. Dr. New originally joined Baxter as a Senior Manager in the Global Renal Marketing franchise, where she was the commercial lead for lifecycle management projects, which included implementation of strategic revenue growth opportunities and development of market access strategies for new markets. Dr. New joined Baxter from Northwestern University, Innovation and New Ventures Office and Feinberg School of Medicine where she was an Entrepreneur in Residence and the Lead Commercialization Consultant for licensing negotiations and alliance management. Dr. New received her PhD from the University of Illinois at Chicago in microbiology and immunology and completed her post-doctoral training at Northwestern University. She also received her MBA from Northwestern University Kellogg School of Management.
